The estimated Net Worth of David Kull is at least 30.3 千$ dollars as of 20 September 2018. Mr Kull owns over 5,000 units of Rockwell Medical Inc stock worth over 30,340$ and over the last 6 years he sold RMTI stock worth over 0$.
Mr has made over 1 trades of the Rockwell Medical Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 5,000 units of RMTI stock worth 15,450$ on 20 September 2018.
The largest trade he's ever made was exercising 5,000 units of Rockwell Medical Inc stock on 20 September 2018 worth over 15,450$. On average, Mr trades about 1,667 units every 0 days since 2018. As of 20 September 2018 he still owns at least 7,400 units of Rockwell Medical Inc stock.
You can see the complete history of Mr Kull stock trades at the bottom of the page.
David J. Kull is the Sec. at Rockwell Medical Inc.
Mr Kull is 53, he's been the Sec. of Rockwell Medical Inc since . There are 13 older and 2 younger executives at Rockwell Medical Inc. The oldest executive at Rockwell Medical Inc is Dr. Russell H. Ellison M.Sc., M.D., MSc., 73, who is the Pres, CEO & Director.
David's mailing address filed with the SEC is C/O ROCKWELL MEDICAL, INC., 30142 WIXOM ROAD, WIXOM, MI, 48393.
Over the last 21 years, insiders at Rockwell Medical Inc have traded over 3,082,721$ worth of Rockwell Medical Inc stock and bought 689,891 units worth 3,959,861$ . The most active insiders traders include Robert L Chioini、David S.Rbi Private Investm...、Thomas E Klema. On average, Rockwell Medical Inc executives and independent directors trade stock every 45 days with the average trade being worth of 170,433$. The most recent stock trade was executed by David S.Rbi Private Investm... on 21 December 2020, trading 42,450 units of RMTI stock currently worth 43,724$.
rockwell medical is a fully-integrated biopharmaceutical company targeting end-stage renal disease (esrd) and chronic kidney disease (ckd) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis. rockwell’s new innovative therapy triferic is the only fda approved drug indicated to replace iron and maintain hemoglobin in hemodialysis patients suffering from anemia. via dialysate during each dialysis treatment, triferic replaces the 5-7 mg iron loss that occurs in all patients, maintaining their iron balance. unlike iv iron products, triferic binds iron immediately and completely to transferrin (carrier of iron in the body) upon entering the blood and is then transported directly to the bone marrow to be incorporated into hemoglobin, with no increase in ferritin (stored iron and inflammation) and no anaphylaxis, addressing a significant unmet need in overcoming functional iron deficiency (fid) in esrd patients. visit www
Rockwell Medical Inc executives and other stock owners filed with the SEC include: